Purchase this article with an account.
Haitao Li, Alex Raffles, Andrew Chang; Intravitreal Triesence for Macular Oedema Treatment: a Case-series Report. Invest. Ophthalmol. Vis. Sci. 2012;53(14):901.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intravitreal Triesence in treating macular oedema.
This clinical interventional case-series study included 143 patients (168 eyes) with macula oedema of variable origin and received at least once of intravitreal Triesence injection. Best corrected visual acuity (BCVA), central subfield retinal thickness and intraocular pressure were examined at baseline, week 1, month 1, month 2 and month 3 after the injection.
Most of eyes had an improved visual acuity during the follow-up comparing to the baseline. BCVA at month 1 had the largest increase (7.4 letter gain), and followed by week 1 (2.3 letter gain) and month 3 (2.2 letter gain). Only a minor loss of 1.4 letter in BCVA was observed at month 2. Eyes with diabetic macular oedema had greater improvement in BCVA than these with vein occlusion (7.4 letter gain vs. 0.8 letter gain at month 3, P<0.05). Central subfield thickness reduced correspondingly after the intravitreal Triescence injection and the greatest reduction was found at week 1 (mean reduction: 163.5μm). Intraocular pressure higher than 25mmHg was found in 5 cases and higher than 30mmHg in 3 cases. No case of endophthalmitis was reported.
Intravitreal Triescence injection was proved to be safe and efficacious in improving visual acuity and reducing central macular thickness in eyes with macular oedema. This study suggests that intravitreal Triescence injection is a promising alternative for treatment of macular oedema.
This PDF is available to Subscribers Only